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Short Communication
Screening for Diseases in Family Practice
Ali Khan Khuwaja, Nadya Khan Khuwaja*
Departments of Family Medicine and Community Health Sciences, Aga Khan University and The Aga Khan Diagnostic Center*, Garden East, Karachi.

Abstract
The active check-over for disease among apparently healthy people is a fundamental aspect of prevention.
This is perceivable by screening, which is a search of
unrecognized disease or condition by means of rapidly
applied test, examination or other procedures in apparently
healthy individuals. This is carried out in the hope that earlier diagnosis and subsequent management favorably alters
the natural history of the disease in a significant proportion
of those who are identified as 'test-positive'.
Family Practitioners have privilege to provide comprehensive and holistic health care services including preventive, curative and rehabilitative on continuous and longterm basis to all members of family irrespective of their
age, sex and nature of disease and condition. Screening of
disease being an important preventive strategy should be
offered by Family Practitioners to their clients when ever
recommended and appropriate.
However, before screening is initiated, a decision
must be made whether it is worthwhile, which requires scientific, financial and ethical justification. This review summarizes the basic concepts and criteria regarding the
screening for diseases.

Introduction
Family Practice is a coordinated, integrated and
comprehensive care provided to individuals and their families in the broad land between health, illness and diseases.
Family Practitioners are engaged with individuals and their
families across the field of cure, care and prevention by
using and integrating the science of biomedicine, medical

psychology, epidemiology and preventive medicine. In this
respect, it also includes early detection and prompt treatment of diseases, thus, preventing and minimizing complications and disabilities.
Prevention is the best strategy to reduce disease burden as well as to decrease substantial direct and indirect
cost that affects the patient, his/her family, society and
health system of the country as a whole. Prevention of disease should be at all levels when it is desirable. Screening
for disease is a major component of the Family
Practitioner's overall preventive responsibility. It allows the
physician to make age and gender specific recommendations modified by the patient's individual risk profile as
determined by family history, previous health history,
health-related behaviors, and environmental and occupational exposure. Screening maneuver applied to apparently
well people to identify those at increased risk of a disease.
Thus the basic purpose of screening is to identify earlier the
persons who are diseased among those who are free from
that particular disease. An implicit assumption underlying
the concept of screening is that early detection of disease,
before the development of symptoms, will lead to a more
favorable prognosis as treatment begun at an earlier stage
of disease will be more effective.
Screening of disease may be done through specific
tests, history and/or clinical examination or implementing
specific questionnaires for that particular condition. A
screening test is not intended to be a diagnostic, it is an initial examination only, and positive responders require a second, diagnostic examination1, that may be more expensive
and painful. For example, if a woman found a lump in breast
during her routine manual breast examination,

should be evaluated further for definitive diagnosis by
mammography and biopsy. However, the criteria are not
hard and fast and there are some tests that are used both for
screening and diagnosis. Test of hemoglobin percentages
for anemia is a good example in this regard.
Screening for disease at their early asymptomatic
stage has played a significant role in public health practice
and now considered as a routine and important aspect of a
good medical care. However, inappropriate application or
interpretation of screening test can rob people of their perceived health, initiate harmful diagnostic testing, and
squander health-care resources.2 Every test is not an ideal
test for screening purpose, as every disease is not an ideal
for screening. There are certain criteria which makes a test
more suitable and appropriate for using as a screening test
and similarly so for disease or disorder to be screened and
the population to whom screening test is to be applied.
Test to be appropriate for screening
An appropriate screening test should be capable of
identifying the people among the population who have a
high probability of being affected by disease or defect and
capable of excluding those who are not affected. In other
words, screening test should identify persons correctly who
are more likely to have a disease among the apparently normal population. A screening test ideally should be valid,
reliable and reproducible. In addition, it should be inexpensive, easy to administer, and impose minimal discomfort on
the person or population to whom it is applied.
The validity of a screening test is measured by its
ability to do what it is supposed to do, that is, correctly categorize persons who have pre-clinical disease as test-positive and those without pre-clinical disease as test-negative.
Sensitivity and specificity are two measure of the validity
of a screening test. Sensitivity of the test is defined as the
ability of the test to identify correctly those who have disease while specificity of the test is defined as the ability of
the test to identify correctly those who do not have disease.3 In other words, sensitivity of the test is the proportion of true positives amongst all those who truly have disease and specificity is the proportion of true negative
amongst all those who truly do not have disease. Hence, it
is desirable to have a screening test that is both highly sensitive and highly specific. However, usually it is not possible, and there is generally a tradeoff between the sensitivity and specificity of a given screening test4, i.e. if sensitivity of test increases the specificity decreases and vice versa.
In addition to sensitivity and specificity, the performance of
a screening test is measured by its predictive values, which
reflects the detection power of the test. The term 'false-positive' means that persons who do not have disease are told
that they have the disease and 'false-negative' denotes that

persons who actually have disease are told that they do not
have. The more prevalent a disease is in a given population,
the more accurate will be the predictive value of a positive
screening test. The predictive value of a positive result falls
as disease prevalence declines. Reliability (repeatability) of
a test refers to the consistency of results when repeat examinations are performed on the same person under the same
conditions. Regardless of the sensitivity, specificity and
predictive accuracy of a test, if the test results cannot be
reproduced, the value and usefulness of the test is minimal.3
Disease to be appropriate for screening
There are some characteristics that make disease
appropriate for screening. To be suitable for screening, the
prevalence of disease should be high among the population
screened, having a long lead time, disease should be serious enough and treatment given at an early stage should be
more beneficial in terms of reducing morbidity, disability
and mortality. The criterion of seriousness relates primarily to issues of cost-effectiveness and ethics. The expenditure of resources on screening must be justifiable in terms
of eliminating or ameliorating adverse health consequences. Similarly, with respect to ethics, the consequences
of failing to diagnose and treat early must be sufficiently
grave to warrant undergoing the risk and discomfort of the
screening procedure itself. For a screening test to be more
fruitful, treatment given during detectable pre-clinical
phase must result in a better prognosis than therapy given
after symptoms develop. Type 2 Diabetes Mellitus (DM),
for example, fulfills all the criteria to be a disease suitable
for screening. First, type 2 DM is a pandemic disease with
higher prevalence worldwide5,6 thus its prevalence in a
screened population is likely to be high. Second, diabetes
remains asymptomatic for a long period of time in majority of subjects and presentation with complications is not
unusual.7,8 Third, it is a serious disease, which leads to
greater number of short-term and long-term complications,
disabilities and premature mortality.9,10 Fourth, early detection and prompt treatment of type 2 DM has shown to
reduce and delays the long term complications.11,12
Hypertension and carcinoma of cervix are other diseases
that are appropriate for screening in their early and asymptomatic stages. On the other hand, for example, lung cancer
has a poor prognosis, regardless of when treatment is initiated thus the application of a screening test will be neither
necessary nor effective for this disease. Other
disorders/conditions which can give high yield for screening in Family Practice set-up includes dyslipidemia in high
risk persons, perinatal screening of congenital and genetic
disorders in high risk women during antenatal check-ups,

includes dyslipidemia in high risk persons, perinatal
screening of congenital and genetic disorders in high risk
women during antenatal check-ups, congenital hypothyroidism during infancy and measurement of intra-ocular
pressure of elderly persons.
Population should be appropriate for screening
To be cost-effective and to get maximum yield,
screening test should be applied for specific group of population having more probability and suspicion of disease to
be present. In other words, the number of cases detected by
screening can be increased by screening high-risk groups
such as targeting breast cancer screening to women with
family history of disease; cervical cancer screening to
women with multiple sex partners and belonging to low
socio-economic status. Diabetes is another good example
in this regard. People who are at higher risk of developing
type 2 DM should be screened when appropriate and
required.
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